Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

€3B Medicines R&D Initiative Approved by EU

Published: Wednesday, April 16, 2014
Last Updated: Tuesday, April 22, 2014
Bookmark and Share
The second Innovative Medicines Initiative (IMI2) is a multi-billion Euro research programme run jointly by the European Commission and the pharmaceutical industry.

IMI is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The objective is to improve the process of developing new drugs, and treatments by supporting cooperation in research and development.

The Parliament was only consulted for advice, as it did not have co-decision rights on this subject, which is left to the European Commission and the Council, representing the 28 EU member states.

The second initiative, spanning the period 2014-2024, will have a budget of approximately €3 billion. It will focus on the development of treatments that contribute to lifelong health and wellbeing, which are expected to gain in importance due to an aging population, and rising levels of chronic and degenerative diseases.

However, not everybody applauded IMI2, with the Green group voting against the initiative.

French MEP Michèle Rivasi said in a statement that she has met regularly with trade unions within the sector. Currently, there is an employment crisis within the pharmaceutical industry in France and in Europe, though the large companies continue to generate 'mind-boggling' profits from patents.

"In this context, SMEs are particularly vulnerable parties. The biggest companies set the research objectives which are then endorsed by the European Commission. They therefore have an actual advantage when funds for research are being distributed. If they want to have access to this public funding for research, SMEs have no choice but to play the game of outsourcing their R&D departments," Rivasi said.

The French MEP added that innovation objectives are not always linked to the real health needs of the population, but rather to the cost of the treatment of a particular disease.

The first IMI initiative, which took place between 2007-2013, funded 40 projects and developed new therapies for patients. According to its promoters, the iniative created nearly 1,500 jobs for a budget of €2 billion, with half of the funding coming from the Commission, and the other half from EFPIA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!